Journal
NATURE REVIEWS CANCER
Volume 12, Issue 7, Pages 494-501Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/nrc3297
Keywords
-
Categories
Funding
- European Union (EU) [HEALTH-F5-2011-282510, HEALTH-F3-2009-223131]
- CHAIN project
- HIV Cell Entry project
- German Ministry of Science and Education (BMBF) [0315480A, 01GS08103]
- Oncogene project
Ask authors/readers for more resources
Drug resistance is a common cause of treatment failure for HIV infection and cancer. The high mutation rate of HIV leads to genetic heterogeneity among viral populations and provides the seed from which drug-resistant clones emerge in response to therapy. Similarly, most cancers are characterized by extensive genetic, epigenetic, transcriptional and cellular diversity, and drug-resistant cancer cells outgrow their non-resistant peers in a process of somatic evolution. Patient-specific combination of antiviral drugs has emerged as a powerful approach for treating drug-resistant HIV infection, using genotype-based predictions to identify the best matched combination therapy among several hundred possible combinations of HIV drugs. In this Opinion article, we argue that HIV therapy provides a 'blueprint' for designing and validating patient-specific combination therapies in cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available